Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 in Relapsed/Refractory CD19+ Lymphomas
NCT02030834Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Feb 2014
- Primary completion
- Sep 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of tisagenlecleucel in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 1 more, sponsored by University of Pennsylvania. Started Feb 2014; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02030834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030834.